[go: up one dir, main page]

AR076564A1 - Anticuerpos humanizados de axl(receptor de tirosina quinasa) - Google Patents

Anticuerpos humanizados de axl(receptor de tirosina quinasa)

Info

Publication number
AR076564A1
AR076564A1 ARP100101604A ARP100101604A AR076564A1 AR 076564 A1 AR076564 A1 AR 076564A1 AR P100101604 A ARP100101604 A AR P100101604A AR P100101604 A ARP100101604 A AR P100101604A AR 076564 A1 AR076564 A1 AR 076564A1
Authority
AR
Argentina
Prior art keywords
axl
kinase
thyrosine
receptor
humanized antibodies
Prior art date
Application number
ARP100101604A
Other languages
English (en)
Inventor
Takeshi Takizawa
Tomoko Takayama
Peter Wirtz
Jens Ruhe
Original Assignee
U3 Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09006355A external-priority patent/EP2270053A1/en
Application filed by U3 Pharma Gmbh filed Critical U3 Pharma Gmbh
Publication of AR076564A1 publication Critical patent/AR076564A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente solicitud se refiere a anticuerpos humanizados monoclonales, que se unen al dominio extracelular de la tirosina quinasa receptora de AXL e inhiben al menos parcialmente la actividad de AXL. Reivindicacion 4: El anticuerpo humanizado monoclonal de acuerdo con cualquiera de las reivindicaciones 1-3, que deriva de uno de los anticuerpos quiméricos Anti-AXL 11B7 (SEC ID Nro.: 135, 136) o 11D5 (SEC ID Nro.: 137, 138) y que contiene por lo menos una mutacion en la region marco de al menos un dominio variable de 11B7 o 11D5.
ARP100101604A 2009-05-11 2010-05-11 Anticuerpos humanizados de axl(receptor de tirosina quinasa) AR076564A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09006355A EP2270053A1 (en) 2009-05-11 2009-05-11 Humanized AXL antibodies
EP09006474 2009-05-13

Publications (1)

Publication Number Publication Date
AR076564A1 true AR076564A1 (es) 2011-06-22

Family

ID=42272537

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101604A AR076564A1 (es) 2009-05-11 2010-05-11 Anticuerpos humanizados de axl(receptor de tirosina quinasa)

Country Status (15)

Country Link
US (2) US8841424B2 (es)
EP (1) EP2430050A1 (es)
JP (2) JP5909442B2 (es)
KR (1) KR20120035145A (es)
CN (1) CN102421802B (es)
AR (1) AR076564A1 (es)
AU (1) AU2010247464B2 (es)
BR (1) BRPI1013428A2 (es)
CA (1) CA2759836A1 (es)
IL (1) IL216147A (es)
MX (1) MX2011011825A (es)
RU (2) RU2571224C2 (es)
TW (2) TWI526223B (es)
WO (1) WO2010130751A1 (es)
ZA (1) ZA201107529B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076564A1 (es) * 2009-05-11 2011-06-22 U3 Pharma Gmbh Anticuerpos humanizados de axl(receptor de tirosina quinasa)
WO2011041721A1 (en) 2009-10-02 2011-04-07 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
EP2707383B1 (en) 2011-05-13 2018-04-18 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
WO2012175691A1 (en) * 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
AU2012273955A1 (en) * 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
WO2014068139A1 (en) * 2012-11-05 2014-05-08 Pierre Fabre Medicament Novel antigen binding proteins and their use as addressing product for the treatment of cancer
EP2931265B3 (en) * 2012-12-14 2023-04-05 The Board of Trustees of the Leland Stanford Junior University Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy
ES2764299T3 (es) * 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
EP3233119A2 (en) 2014-12-18 2017-10-25 Bergen Teknologioverforing AS Anti-axl antagonistic antibodies
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
US10787517B2 (en) 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
AU2016292762B2 (en) 2015-07-10 2022-07-28 Genmab A/S AXL-specific antibody-drug conjugates for cancer treatment
EP4349997A3 (en) 2015-09-24 2024-07-10 Daiichi Sankyo Company, Limited Anti-garp antibody
AU2017248644B2 (en) * 2016-04-15 2019-10-31 Bioatla, Llc Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
MX2019012464A (es) 2017-04-20 2019-12-11 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
CN110540592B (zh) 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
CN109160941B (zh) * 2018-09-29 2020-09-04 未名生物医药有限公司 蛋白序列17e11及其用途
RU2678569C1 (ru) * 2018-10-31 2019-01-30 Гордейчук Владимир Евгеньевич Способ подавления метастазирования опухолей
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN110982791A (zh) * 2019-12-26 2020-04-10 百泰生物药业有限公司 一种分泌axl抗体的杂交瘤细胞的制备筛选方法
CA3164037A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
JP2023521753A (ja) 2020-04-08 2023-05-25 ベルゲンビオ アーエスアー 抗ウイルス療法
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
WO2022164288A1 (ko) 2021-01-29 2022-08-04 한국과학기술원 비염증성 식세포작용 유도 활성을 갖는 융합분자
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
CN115927243A (zh) * 2022-09-13 2023-04-07 中山大学 一种akt1蛋白的抑制性磷酸化位点及其应用
CN116715774B (zh) * 2023-05-12 2023-11-24 武汉爱博泰克生物科技有限公司 针对人axl的兔单克隆抗体及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
DE3900534A1 (de) 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
JP2000511403A (ja) 1996-03-20 2000-09-05 イムノメディクス，インコーポレイテッド 抗癌胎児抗原抗イディオタイプ抗体のヒト化と腫瘍ワクチンとしての使用及びターゲッティング用途のための使用
EP1190061A1 (en) 1999-06-07 2002-03-27 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US7910100B2 (en) 2004-10-01 2011-03-22 Max-Planck-Gesellschaft zur Forderung der Wissen Antibodies directed to the mammalian EAG1 ion channel protein
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
WO2006105062A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
EP1891110A2 (en) 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
WO2009005813A1 (en) 2007-07-02 2009-01-08 Wyeth Modulators of axl for use in treating bone disorders
WO2010008411A1 (en) * 2007-11-09 2010-01-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
EP2918605A1 (en) * 2007-11-12 2015-09-16 U3 Pharma GmbH Axl antibodies
AR076564A1 (es) * 2009-05-11 2011-06-22 U3 Pharma Gmbh Anticuerpos humanizados de axl(receptor de tirosina quinasa)

Also Published As

Publication number Publication date
KR20120035145A (ko) 2012-04-13
AU2010247464A1 (en) 2011-11-10
TW201105348A (en) 2011-02-16
BRPI1013428A2 (pt) 2019-07-02
JP2012526530A (ja) 2012-11-01
CN102421802A (zh) 2012-04-18
US8841424B2 (en) 2014-09-23
WO2010130751A1 (en) 2010-11-18
CN102421802B (zh) 2014-08-20
US20120117670A1 (en) 2012-05-10
JP5909442B2 (ja) 2016-04-26
US20150037323A1 (en) 2015-02-05
AU2010247464B2 (en) 2014-09-11
TW201509431A (zh) 2015-03-16
IL216147A (en) 2016-04-21
RU2571224C2 (ru) 2015-12-20
TWI526223B (zh) 2016-03-21
MX2011011825A (es) 2011-12-06
CA2759836A1 (en) 2010-11-18
JP2016011306A (ja) 2016-01-21
IL216147A0 (en) 2012-01-31
RU2011150183A (ru) 2013-06-20
EP2430050A1 (en) 2012-03-21
ZA201107529B (en) 2012-06-27
RU2015147287A (ru) 2017-05-12

Similar Documents

Publication Publication Date Title
AR076564A1 (es) Anticuerpos humanizados de axl(receptor de tirosina quinasa)
ES2722300T3 (es) Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
MY155621A (en) Axl antibodies
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
ES2500066T3 (es) Anticuerpos frente a ferroportina y métodos de uso
MX2011013781A (es) Anticuerpos anti-vegf y sus usos.
MX2021015141A (es) Anticuerpos anti-receptor de transferrina con afinidad diseñada.
ES2658224T3 (es) Anticuerpos humanizados contra receptores de tipo Toll 2 y sus usos
NO20085104L (no) Antagonistisk anti-humant CD40-monoklonalt antistoff
CO6150194A2 (es) Anticuerpos prlr-especifico y usos del mismo
EA201001467A1 (ru) Моноклональное антитело и способ его использования
MX371384B (es) Receptor antigenico quimerico.
NI201400019A (es) Anticuerpo anti-alfabetatcr
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
MX2011009312A (es) Formulaciones de anticuerpos humanizados anti-cd19.
MX387324B (es) Variantes de regiones fc de igg1 de humano y usos de las mismas.
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
CO6231000A2 (es) Anticuerpos contra de erbb3 y usos de los mismos
MX2012002458A (es) Anticuerpos anti-cdcp1 humanizados.
MX352599B (es) Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.
ES2537017T3 (es) Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano
ES2722824T3 (es) Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)
PE20121560A1 (es) Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana
AR073140A1 (es) Anticuerpos anti-il-23r disenados

Legal Events

Date Code Title Description
FB Suspension of granting procedure